Angiolab, Inc., a biotechnology company, develops medicine with angiogenesis inhibitors for treating angiogenesis-related diseases. Its Phase I products consist of AL101-PSO for psoriasis. The company’s Phase II a clinical trial products include AL101- NASH for the treatment of non-alcoholic steatohepatitis; AL101-OME, for otitis media with effusion; and AL102-PDT for periodontitis. Its Phase II clinical trial products comprise AL101-AMD to treat age related muscular degeneration; and AL101-AOB for the treatment of abnormal obesity. In addition, the company provides ob-X for visceral fat reduction; and specific function and health functional food. Further, it offers AL201-AB, which is in the pre-clinical stage for the treatment of cancer, ocular diseases, etc. The company was founded in 1999 and is headquartered in Daejeon, South Korea.
तुलना करने के लिए मीट्रिक्स | 251280 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत कंस्यूमर नॉन-साइक्लिकल्स | संबंध संबंध251280पीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | 0.0x | −4.2x | −0.5x | |
PEG अनुपात | 0.00 | −0.08 | 0.00 | |
क़ीमत/बुक | 0.0x | 2.8x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 0.0x | 24.6x | 2.9x | |
अपसाइड (विश्लेषक लक्ष्य) | 0.0% | 19.8% | 49.4% | |
उचित मूल्य अपसाइड | अनलॉक करें | 3.3% | 8.2% | अनलॉक करें |